Show Notes
N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Zak Mir talks to Dr Kerim Sener, Managing Director, Ariana Resources
Zak Mir speaks with Dr Kerim Sener, Managing Director of Ariana Resources (AIM: -
Zak Mir talks to Ajax Resources CEO Ippolito Cattaneo
Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources, as the natural resour -
Gelion’s John Wood discusses latest developments with Zak Mir
Zak Mir speaks with John Wood, CEO of Gelion (AIM: GELN), following the release -
Zak Mir spoke with Australian Gold and Copper Ltd (ASX:AGC) MD Glen Diemar on today’s Achilles results
Achilles Northern Zone Delivers Exceptional Grades AGC Managing Director, Glen